fluoxetine in sepsis

Effect of fluoxetine on Organ Dysfunction and Mortality in Severe Sepsis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202412745051519

Enrollment

100

Registered

2024-12-23

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System sepsis Surgery

Interventions

fluoxetine

placebo capsule starch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • ASA II, III aged 18-65 years, BMI 30-35, admitted to ICU and diagnosed as patients with severe sepsis. • The diagnosis of severe sepsis was established according to the definitions of the Surviving Sepsis Campaign (SSC

Exclusion criteria

Exclusion criteria: • Patients with Late septic shock at presentation with multiple organ failure • APACHE II score on admission >25 • Preexisting liver cirrhosis • patients with prolonged QT interval or premature ventricular beats • Preexisting end-stage renal disease • Pregnancy • History of allergy to fluoxetine • Patients with malignancies • Uncontrolled hemorrhage • Burns • Previous steroid therapy • Death within 24 hours of ICU admission • Concurrent use of MAO inhibitors or linezolid or any drugs increase QR interval like flecainde • History of seizures • Age more than 65 years

Design outcomes

Primary

Measure	Time frame
oNeed for and duration of vasopressor and inotropic support	—

Secondary

Measure	Time frame
ICU Mortality & Organ dysfunction	—

Countries

Egypt

Contacts

Public Contactlobna saleh

associated professor ain shams university

lobnasaleh_80@yahoo.ca00201005246397

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026